Article Figures & Data
Figures
- Figure 1.
Comparison of the efficacy slopes and absolute changes for donepezil and lecanemab versus placebo. Improvement from the baseline was only observed for donepezil. In both cases, visual divergence in the curves suggested the possibility of greater benefits beyond the short window of the trials. Note the scale of Y axis is equal in both studies, facilitating comparison. IV, intravenous. ADAS-Cog, cognitive subscale of the Alzheimer's Disease Assessment Scale; range 0–90, higher means worse. The MCID for this scale is 3 points. Adapted from data in Rogers (1998) and van Dyck et al. (2023).
- Figure 2.
Infographic of the lecanemab pivotal trial. The data are shown to facilitate a comprehensive interpretation of the clinical trial data in the authors’ perspective.
- Figure 3.
Infographic of the donanemab pivotal trial. The data are shown to facilitate a comprehensive interpretation of the clinical trial data in the authors’ perspective.
In this issue
